ABSTRACT
QUESTION
What is the role of oxaliplatin combined with 5-fluorouracil (5-FU) and folinic acid (FA) in the first-and second-line treatment of advanced (unresectable locally advanced or metastatic) colorectal cancer?
Outcomes of interest were 1-year survival, response rates, and quality of life (QOL).
CHOICE OF TOPIC AND RATIONALE
In Ontario, Canada, colorectal cancer is the fourth most common cancer site for both sexes combined, representing 13 .1% of all new cancer cases 1 . Colorectal cancer is the third most common site in men (13.3% of all new cases) and the second most common site in women (12. 9% of all new cases) 1 , and it remains the second leading cause of cancer death (10.6% of all cancer deaths) 1 . Considering both men and women, colorectal cancer ranks third as the leading cause of death after breast and lung cancers in females and after lung and prostate cancers in males 1 . For that reason, interest in improving the treatment results for this group of patients is great.
Currently, the standard first-line treatment for metastatic colorectal cancer (MCC) in Canada is a combination of 5-FU, FA [also known as leucovorin calcium (LV)], and irinotecan-called FOLFIRI-delivered by infusion (Douillard regimen) 2 . Infusional FOLFIRI replaced IFL, which is the same drug combination by bolus delivery. For patients unable to tolerate a combination-therapy regimen, an alternative to FOLFIRI is monotherapy with a first-line thymidylate synthase (TS) inhibitor such as 5-FU/LV, raltitrexed 3 , or capecitabine, followed by second-line irinotecan alone 4 .
Once patients are no longer responding to the combined use of a TS inhibitor and irinotecan or to monotherapy, the options for treatment are limited. Oxaliplatin, a third-generation platinum compound has demonstrated activity in colorectal cancer. Oxaliplatin differs from both cisplatin and carboplatin in its amino acid configuration. Oxaliplatin has an oxalato group that is removed by hydrolysis and replaced with a diaminocyclohexane (DACH) group 5 . The bulky DACH side groups inhibit DNA base excision by mismatching the repair enzymes 5 . Because repair enzymes are particularly active in colorectal cancer, oxaliplatin has the potential to be of great benefit to patients in both first-and second-line treatment. With the availability of randomized trials comparing combination regimens of oxaliplatin and 5-FU/FA with other combinations, a systematic review of the evidence and clinical practice guideline were warranted.
METHODS

Guideline Development
This systematic review was developed by the Gastrointestinal Cancer Disease Site Group (GI DSG) of Cancer Care Ontario's Program in Evidence-Based Care (PEBC), using the methods of the practice guidelines development cycle 6 . Evidence was selected and reviewed by two members of the GI DSG and by a methodologist.
The body of evidence in this review is primarily composed of data from mature randomized controlled trials (RCTs). The systematic review and clinical practice guideline are intended to promote evidence-based practice in Ontario, Canada. The PEBC is editorially independent of Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.
Literature Search Strategy
A systematic search of the MEDLINE neoplasms," "rectal neoplasms," and "colorectal neoplasms" were combined with the text words "oxaliplatin", "L-OHP," "LOHP," and "FOLFOX". The results from that search were then combined with the terms "random" and "clinical trial" describing specific study designs. Results were limited to the English language. The conference proceedings of the 1999 to 2006 annual meetings of the American Society of Clinical Oncology, including the 2004 through 2006 gastrointestinal cancer symposia, were also searched for reports of new or ongoing trials. The reference lists from retrieved papers were searched for additional trials.
Study Selection Criteria
Articles were selected for inclusion in this systematic review of the evidence if they were
• phase III RCTs of oxaliplatin (L-OHP) combined with 5-FU/FA as first-line or second-line therapy for advanced colorectal cancer.
• abstract reports of trials.
• English-language published reports.
Synthesizing the Evidence
For the following reasons, the GI DSG decided not to pool the results of the trials found in the literature search:
• Treatments described were too heterogeneous to allow for pooling.
• Evidence from the studies obtained provided a clear indication of benefit or harm.
• Published meta-analyses of individual patient data were available. (The meta-analyses are discussed in the appropriate sections of this report.)
RESULTS
Literature Search Results
The literature search found thirty-three reports , including twenty-seven reports on randomized controlled trials (RCTs) of first-line treatment [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [31] [32] [33] [34] [35] [36] [37] , involving seventeen separate [31] [32] [33] [34] [35] [36] [37] ; two meta-analyses on first-line treatment 28, 29 ; and four reports on second-line treatment 17, 30, 38, 39 . Ten of these reports were preliminary publications that provided additional information about the included trials [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . Of the thirty-three trial reports obtained, twelve were fully published 7, 8, 10, 11, 15, 16, 28, 31, 32, 34, 35, 37 , and twentyone were available in abstract form only 9, [12] [13] [14] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] 29, 30, 33, 36, 38, 39 . Of the seventeen main reports on first-line treatment, six were available as abstracts only 9, [12] [13] [14] 33, 36 . All four reports on second-line treatment were available as abstracts only 17, 30, 38, 39 . Sixteen of the included trial reports disclosed funding, either wholly or in part, from pharmaceutical companies 7, 8, 10, 11, [15] [16] [17] [20] [21] [22] 27, 30, 31, 39 . Seven reported Debiopharm as the source of funding 7, 8, 10, 11, [20] [21] [22] ; one reported Pharmacia (Pfizer) / Sanofi-Synthelabo 15 ; two reported Aventis 16, 27 ; one reported Aventis / Sanofi-Synthelabo 31 ; and three reported SanofiSynthelabo 17, 30, 39 . Five of the reports disclosed a hospital, university, research group, or another non-industry entity as the source of funding [32] [33] [34] [35] 37 , and twelve trials did not report the source of funding 9, [12] [13] [14] 18, 19, [23] [24] [25] [26] 36, 38 . The reported sources of funding for the two obtained meta-analyses were a research group grant 28 and partial industry funding 29 . (Table I ). Six reports of these seventeen trials were available in abstract form only 9, 12, 13, 14, 33, 36 . Results for the outcomes of interest follow.
Outcomes
1-Year Survival:
Only seven of the seventeen trials reported 1-year survival data 8, 10, 11, 15, 31, 32, 35 . One of the trials 8 compared two regimens that both contained 5-FU, FA, and oxaliplatin: one in a standard infusion, and the other in a chronomodulated regimen. Both arms reported similar 1-year survival rates (66% vs. 63%, p > 0.05). Of the other six trials, only two detected statistically significant 1-year survival differences: one for FOLFOX4 over IFL (71% vs. 58%, p = 0.002) 15 , and another for OXAFAFU over IRIFAFU (39% vs. 23%, p = 0.032) 31 .
Response Rates: Only two of the seventeen trials did not report data on response rates 9, 12 . Nine of the 15 trials reported statistically significant differences (p < 0.05) in response rates between treatment arms: three for chronomodulated regimens of 5-FU, FA, and oxaliplatin over standard infusion regimens of the same agents 7, 8, 11 ; and the others for LV5FU2 and oxaliplatin over LV5FU2 alone 10 
Quality of Life:
Only two of the seventeen RCTs reported data on QOL 10, 34 . Of these latter two trials, neither reported a significant difference in QOL scores between the trial arms: LV5FU2 plus oxaliplatin versus LV5FU2 10 , or OXAFAFU versus FAFU 33 .
As reported in the RCTs located by the literature search, first-line treatment with oxaliplatin was associ-JONKER et al. ated with significantly more peripheral and sensory neuropathy and neutropenia beyond the adverse effects expected with the other drugs given in the regimen.
Meta-analyses of First-line Trials
The meta-analysis reported by Grothey et al. 28 included the fully published or publicly presented results from seven RCTs involving 3186 patients. It detected a significant 3.5-month increase in median survival (p = 0.0083) in patients who received a firstline combination therapy (either oxaliplatin/5-FU/FA or irinotecan/5-FU/FA) as compared with patients who received monotherapy. The results of the meta-analysis indicated that, for maximum overall survival benefit, patients on a first-line combination therapy containing oxaliplatin should be offered combination therapy with irinotecan as second-line treatment, and vice versa. It appears that second-line treatment may compensate for a less active first-line treatment, as evidenced by the fact that patients who had access to all three active drugs (oxaliplatin, irinotecan, and 5-FU) showed the longest overall survival. However, this conclusion is confounded by the fact that patients who lived longer were more likely to have been treated with all three drugs. In addition, patients with lower performance status may have been excluded from second-line treatments using oxaliplatin and irinotecan. Additionally, oxaliplatin was not available to all patients, especially in older trials. The metaanalysis detected longer median survival times in more recent trials-trials more likely to use oxaliplatin in first-and second-line treatment. An abstract report by Lévi et al. 29 pooled the 7-year results of two previously discussed, but individually underpowered, trials 7, 8 . Both trials compared chronomodulated (CM) infusion to flat infusion in the first-line treatment of MCC. Significant benefits were detected in overall response rate (ORR%: 51% vs. 30%; p < 0.001), complete surgical resection (23.3% vs. 12.8%, p < 0.001), and median progression-free survival (PFS: 10.3 months vs. 7.5 months; p = 0.039) favouring CM therapy; however, no difference was detected in median survival (18.6 months vs. 16.5 months, p = 0.22). Pooling the data from the two trials did not detect any difference in survival at either 5 or 7 years (5-year survival: 12.6% vs. 15.2%; 7-year survival: 6.6% vs. 7.1%). The results may have been confounded by an imbalance between the studies with regard to recurrent metastatic disease following surgery for liver metastases (10% of patients receiving flat infusion vs. 22% of patients receiving CM infusion, p < 0.001), and in addition, by significant treatment crossover from the flat infusion to the CM infusion arm (26% of patients), which affected median survival (14.7 months non-crossover vs. 18.5 months crossover; p = 0.043). The pooled results from those two trials confirmed that, as compared with flat infusion, CM infusion significantly improved the ORR% and PFS.
Phase III RCTs of Oxaliplatin Combined with 5-FU and FA as Second-line Therapy for Advanced Colorectal Cancer
Four reports 17, 30, 38, 39 describing four RCTs of secondline treatment were obtained (Table I ). All of these trial reports were available in abstract form only.
1-Year Survival:
None of the second-line treatment reports obtained provided data on 1-year survival.
Response Rates: Three of the four reports 17, 30, 39 provided data on response rates. All three trials reported statistically significant differences between the trial arms, two for FOLFOX4 over LV5FU2 17, 30 (9.9% vs. 0%, p < 0.0001 30 ; 11.1% vs. 1.9%, p < 0.05 17 ) , and the third for the sequence FOLFOX4→CPT-11 over CPT-11→ FOLFOX4 (27% vs. 15%, p < 0.0142) 39 . Quality of Life: None of these abstract reports provided data on QOL.
As indicated under the heading "Quality of Life" in subsection 4.2.1, treatment with oxaliplatin was associated with significantly more peripheral and sensory neuropathy and neutropenia beyond the adverse effects expected from other drugs given in the regimen.
INTERPRETIVE SUMMARY
The combination regimens using infusional 5-FU (FOLFOX or FOLFIRI) both represent acceptable treatment alternatives for first-line therapy in fit patients.
Oxaliplatin is active in colorectal cancer, and the evidence supports its use in combination with infusional 5-FU/FA (FOLFOX). Oxaliplatin without 5-FU/FA does not appear to have meaningful activity. The FOLFOX regimen has definite advantages over bolus IFL in terms of toxicity, objective response rate (45% vs. 31%), median TTP (8.7 months vs. 6.9 months), median survival (19.5 months vs. 15.0 months), and 1-year survival (71% vs. 58%) as demonstrated in the N9741 study 15 .
The superior 1-year survival seen in the N9741 study may have two possible explanations:
• The 5-FU was given as an infusion in the FOLFOX arm, but as a bolus in the IFL arm, and infusional 5-FU has demonstrated superiority over bolus 5-FU in terms of toxicity and tumour response rate. This fact alone may therefore account for the differences seen in the two regimens. It may also account for the lack of difference seen between FOLFOX and FOLFIRI in the GERCOR study, because both regimens used infusional 5-FU 16 27 . It is also evident that when combination therapy is to be used, infusional rather than bolus 5-FU should be used. This recommendation to use 5-FU in an infusional schedule is now abundantly clear from single-agent studies, from combination studies in advanced disease, and from the adjuvant setting in early colorectal cancer. The role of bolus 5-FU in the management of colorectal cancer is becoming increasingly limited.
The combination of oxaliplatin and irinotecan is also active, but it has lower tumour response rates and 1-year survival rates than FOLFOX does, and therefore no advantages 15 .
The inconvenience of infusional 5-FU pump programs, in combination with the drug's unavailability in certain regions, has led to interest in oral capecitabine as a possible replacement for infusional 5-FU in oxaliplatin and irinotecan combinations. The few phase II trials reported thus far have demonstrated response rates and toxicity that appear comparable to those seen with infusional 5-FU combinations. In the future, capecitabine may supersede the 5-FU pump and the need for central venous access devices; however, this development will depend on the results of ongoing phase III trials. Until the results of those trials are available, infusional 5-FU regimens-either alone or in combination-are standard therapy.
The question of whether to use a CM regimen of infusional 5-FU is a compelling area of study, but no such regimen has been widely evaluated outside of a few specialized centres. This question extends beyond a simple review of 5-FU/oxaliplatin combinations. The pooled analysis of the two underpowered studies by Lévi et al. 7, 8 suggests that CM could both reduce toxicity and positively affect endpoints such as ORR% and TTP. The intervention is worthy of further study, although the complexity of the therapy may put it beyond feasibility in many locales.
The ECF4584 trial 30 demonstrated improvements in response rate, TTP (median: 4.6 months vs. 1.6 months, p < 0.0001), and symptom control with second-line FOLFOX as compared with oxaliplatin alone or infusional 5-FU/FA alone in patients who progressed on the ILF regimen. No overall survival analysis was performed. For patients who have progressed on both an anti-TS agent and irinotecan, FOLFOX is the preferred therapy.
In patients with tumour progression on first-line 5-FU/FA, FOLFOX is active, with an ORR% that appears to compare favourably with that of FOLFIRI, the standard regimen. Currently, more evidence supports second-line irinotecan than supports FOLFOX or oxaliplatin alone, but for patients considered poor candidates for second-line irinotecan, FOLFOX is a reasonable alternative. Further clarification of the role of oxaliplatin after progression on first-line 5-FU awaits more-mature data from the Sanofi-sponsored ECF4585 trial.
As treatment regimens for advanced colorectal cancer continue to evolve, recent trials 38, 40 have investigated the addition of bevacizumab to the FOLFOX regimen. An abstract report by Hochster et al. 40 of the TREE-2 study-a first-line cohort study comparing FOLFOX plus bevacizumab, OXAFAFU plus bevacizumab, and capecitabine and oxaliplatin (CAPOX) plus bevacizumab-found that FOLFOX plus bevacizumab resulted in the longest median survival with acceptable adverse events. In the TREE-2 study, the median survivals for the treatment arms without bevacizumab were 19.2 months (FOLFOX), 17.9 months (OXAFAFU), and 17.3 months (CAPOX) as compared with 26 months (FOLFOX + bevacizumab), 20.7 months (OXAFAFU + bevacizumab), and 27.0 months (CAPOX + bevacizumab) 41 . The overall median survival was 18.2 months (no bevacizumab) as compared with 24.4 months (bevacizumab added) 41 . When the overall survival data from the TREE-1 trial (no bevacizumab) were compared with the TREE-2 trial data (bevacizumab added), the results were 12 months, 67.5% versus 79.1%; 18 months, 50.1% versus 64.7%; 24 months, 35.8% versus 50.7%-all in favour of the treatments including bevacizumab 41 .
The second-line RCT reported by Giantonio et al. 38 , which compared FOLFOX4 with and without bevacizumab, found that the addition of bevacizumab to the FOLFOX regimen resulted in significant gains in both median survival (10.7 months vs. 10.2 months, p = 0.0024) and PFS (7.4 months vs. 5.5 months, p = 0.0003). Based on these two trials, we conclude that the addition of bevacizumab to an infusional 5-FU, FA, and oxaliplatin regimen may provide benefits beyond those that would be possible with infusional 5-FU, FA, and oxaliplatin without bevacizumab.
GASTROINTESTINAL CANCER DSG CONSENSUS PROCESS
Note: The GI DSG consensus process was based on an earlier draft of the present document. That draft did not contain any of the evidence regarding the addition of bevacizumab to regimens of infusional 5-FU/FA plus oxaliplatin. References 15 and 31-41 were added to the document after the consensus process took place. The systematic review found one first-line therapy trial 15 that demonstrated infusional 5-FU/FA/ oxaliplatin (FOLFOX) to be superior to bolus 5-FU/FA/ irinotecan (IFL), with more favourable rates of median survival and tumour response. Compared with IFL, FOLFOX has lower incidences of severe nausea, vomiting, diarrhea, and febrile neutropenia, but a higher incidence of peripheral neuropathy. Therefore, for first-line treatment, short-term infusional 5-FU/FA in combination with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) is acceptable for fit patients when combination therapy is the preferred treatment. Choice of first-line therapy may rely on patient factors and preferences-for example, less neuropathy with irinotecan versus less alopecia with oxaliplatin.
For second-line treatment after progression on first-line anti-TS monotherapy (for example, 5-FU/FA, capecitabine), irinotecan is standard therapy. For patients with contraindications to the use of secondline irinotecan, FOLFOX is a reasonable alternative. After progression on both irinotecan and an anti-TS agent, FOLFOX is the preferred therapy.
The role of radiation therapy, either alone or in combination with chemotherapy, for locally advanced unresectable colorectal cancer was not addressed in this guideline. In addition, the use of CM regimens is a topic that intersects with the use of oxaliplatin/5-FU combinations, particularly CM 5-FU in those combinations. Chronomodulation of oxaliplatin has not been extensively studied and was not addressed, because the topic is beyond the scope of this guideline.
In conclusion, the GI DSG acknowledges that the combination of oxaliplatin with short-term infusional 5-FU and FA (FOLFOX) is an important component of first-and second-line treatment of advanced colon cancer, and the DSG recommends that oxaliplatin be made available for the treatment of advanced colorectal cancer.
EXTERNAL REVIEW OF THE PRACTICE GUIDELINE REPORT
Note: The practitioner feedback survey was based on an earlier draft of the present document. That draft did not contain any of the evidence regarding the addition of bevacizumab to infusional regimens of 5-FU/FA plus oxaliplatin. References 15 and 31-41 were added to the document after the practitioner feedback survey was complete. Based on the evidence and the draft recommendations presented at the time of GI DSG consensus, feedback was sought from Ontario clinicians.
Methods
Practitioner feedback was obtained through a mailed survey of 63 practitioners in Ontario (11 medical oncologists, 9 radiation oncologists, 42 surgeons, and one other practitioner). The survey consisted of items evaluating the methods, results, and interpretive summary used to inform the draft recommendations and asking whether the draft recommendations should be approved as a practice guideline. Written comments were invited. The practitioner feedback survey was mailed September 15, 2004 . Follow-up reminders were sent at 2 weeks (post card) and 4 weeks (complete package mailed again). The GI DSG reviewed the results of the survey.
Results
From among the 63 surveys distributed, 29 responses were received (46% response rate). "Responses" include returned completed surveys and telephone, fax, and e-mail responses. Of the practitioners who responded, 18 indicated that the report was relevant to their clinical practice, and they completed the survey. Table II summarizes key results of the practitioner feedback survey.
Summary of Written Comments
Four respondents (22%) provided written comments. The main points were these:
• Access issues with oxaliplatin are ongoing.
• The guidelines seem to be directed to the medical oncologists who provide the treatments. For other caregivers in the cancer system, this key message needs to be delivered: Cancer treatment is in a state of continuous development with increasing efficacy, therefore assessment by a medical oncologist is important for all patients.
• Some of the stated recommendations are currently in use and are being accepted with enthusiasm by both clinicians and patients.
• This guideline has not included any information regarding the role of radiation in the local management of rectal tumours. However, the guideline makes good sense with respect to the recommended chemotherapy regimens. Could a recommendation, or at least a comment, be added somewhere in the document regarding radiation timing, and radiation in combination with the recommended chemotherapy regimens?
Modifications/Actions
The GI DSG made the following modifications to the clinical practice guideline in response to the comments obtained during practitioner feedback:
• With respect to the ongoing access issues with oxaliplatin, the GI DSG acknowledges the major barrier that access represents to putting its recommendations into practice. The GI DSG hopes that their recommendation of oxaliplatin will raise awareness of the issue and facilitate the process of making this drug available to patients.
• With respect to the issue of radiation therapy, the GI DSG added a qualifying statement to both the abstract and the main document: "The role of radiation therapy, either alone or in combination with chemotherapy, for locally advanced unresectable colorectal cancer is not addressed in this guideline." If this report were to become a practice guideline, 67 11 11 how likely would you be to make use of it in your own practice?
